Jesse Yu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 7

Top Topics

Emergency Department

Pluripotent Stem Cells

Pulmonary Arterial Hypertension

Top Venues

Drug metabolism and disposition: the biological fate of chemicals

Biopharmaceutics & drug disposition

This page only lists publications with an associated author ORCID identifier.

Publications

Jesse Yu, Fei Tang, Fang Ma, Susan Wong, Jing Wang, Justin Ly, Liuxi Chen, Jialin Mao
Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment. Drug metabolism and disposition: the biological fate of chemicals 52 (8) (2024)
Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J Y Ho
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression. Cancers 16 (16) (2024)
Jesse Yu, Fei Tang, Fang Ma, Susan Wong, Jing Wang, Justin Ly, Liuxi Chen, Jialin Mao
Human Pharmacokinetic and CYP3A Drug-Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment. Drug metabolism and disposition: the biological fate of chemicals 52 (8) (2024)
Jesse Yu, Xiaolin Xu, James Ian Griffin, Qingxin Mu, Rodney J Y Ho
Drug Combination Nanoparticles Containing Gemcitabine and Paclitaxel Enable Orthotopic 4T1 Breast Tumor Regression. Cancers 16 (16) (2024)
Jesse Yu, Fei Tang, Fang Ma, Susan Wong, Jing Wang, Justin Ly, Liuxi Chen, Jialin Mao
Human Pharmacokinetic and CYP3A DDI Prediction of GDC-2394 using PBPK Modeling and Biomarker Assessment . Drug metabolism and disposition: the biological fate of chemicals (2024)
Jialin Mao, Fang Ma, Jesse Yu, Tom De Bruyn, Miaoran Ning, Christine Bowman, Yuan Chen
Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds. Biopharmaceutics & drug disposition (2023)
Linxi Zhu, Qingxin Mu, Jesse Yu, James I Griffin, Xiaolin Xu, Rodney J Y Ho
ICAM-1 Targeted Drug Combination Nanoparticles Enhanced Gemcitabine-Paclitaxel Exposure and Breast Cancer Suppression in Mouse Models. Pharmaceutics 14 (1) (2021)